Category Archives: EQS Newsfeed

DEBRA Research Invests in Topadur to Advance Small-Molecule Therapies for Dystrophic Epidermolysis Bullosa

Posted on by

Topadur Pharma AG

/ Key word(s): Financing

DEBRA Research Invests in Topadur to Advance Small-Molecule Therapies for Dystrophic Epidermolysis Bullosa

28.10.2026 / 11:00 CET/CEST

The issuer is solely responsible for the content of this announcement.

DEBRA Research Invests in Topadur to Advance Small-Molecule Therapies for Dystrophic Epidermolysis Bullosa

Preclinical program will evaluate Topadur’s proprietary, locally acting compounds, including clinical-stage TOP-N53, which target key disease processes in dystrophic Epidermolysis bullosa, a rare and debilitating genetic skin disorder

Munich, Germany, and Schlieren-Zurich, Switzerland, 28 October 2026 – DEBRA Research gGmbH, a global non-profit organization dedicated to advancing research and drug development for Epidermolysis bullosa (EB), and Topadur Pharma AG, a Swiss clinical-stage biopharmaceutical company, today announced an investment by DEBRA Research in Topadur to support a preclinical program exploring a new treatment approach for dystrophic Epidermolysis bullosa (DEB). DEB is one of the more severe forms of EB, characterized by extremely fragile skin and progressive, debilitating complications.

The program will evaluate Topadur’s clinical-stage compound TOP-N53 together with additional selected small molecules from its proprietary DualTOP® platform. The compounds will be investigated in in vitro and in vivo models addressing two major and interconnected challenges in DEB: impaired wound healing and fibrosis. The studies will be conducted in collaboration with the Medical Center – University of Freiburg, Germany, and EB Research Institute GmbH in Salzburg, Austria.

“People living with dystrophic EB face severe complications that extend far beyond chronic wounds,” said Prof. Hubert Trübel, MD, MBA, Managing Director of ReadOn Therapeutics, a DEBRA Research spinout. “Through our investment in Topadur, we are supporting the development of locally acting therapies that target several interconnected aspects of the disease. We see this as an important step toward exploring new approaches that go beyond wound management alone.”

“DEBRA Research brings deep expertise in EB and a strong understanding of the needs of people living with this devastating disease. Their support as an investor and partner in this program is an important endorsement of our approach and underscores the broader potential of our DualTOP® platform in indications with significant unmet medical needs,” said PD Dr. Matthias Schäfer, CEO of Topadur Pharma AG.

EB comprises a group of rare genetic conditions characterized by extremely fragile skin that is prone to blistering and wounds, even from minor friction or trauma. In DEB, mutations in the COL7A1 gene impair collagen VII, resulting in recurrent skin lesions within the dermis. Repeated cycles of injury and repair can lead to chronic wounds, progressive fibrosis, scarring, and severe functional impairment. Despite recent advances in wound treatment, there is still a significant need for therapies addressing these interconnected disease processes.

Topadur’s DualTOP® platform comprises locally acting small molecules designed to modulate complementary signalling pathways involved in tissue repair and disease progression. TOP-N53, Topadur’s lead asset, has demonstrated wound-healing activity in preclinical models and increased local skin perfusion in a first-in-human Phase 1 study, where it was well tolerated. It is currently in Phase 2a clinical development for digital ulcers in systemic sclerosis and has received Orphan Drug Designation from both the FDA and EMA. Across the broader DualTOP® platform, Topadur compounds have also demonstrated anti-fibrotic activity in preclinical models. The DEB program will investigate these complementary properties in disease-relevant models.

About Topadur Pharma AG

Topadur Pharma AG, based in Schlieren-Zurich, Switzerland, is a clinical-stage biopharmaceutical company developing locally acting small-molecule therapies. Its proprietary DualTOP® platform targets the cGMP signalling pathway, a central regulator of vascular regeneration and tissue repair. Building on this technology, the company is advancing a pipeline of therapeutic candidates for age- and disease-related conditions with significant unmet medical needs. Topadur’s lead candidate, TOP-N53, is undergoing Phase 2a clinical evaluation for the treatment of digital ulcers in patients with systemic sclerosis. In parallel, TOP-M119 is being prepared for first-in-human clinical trials targeting alopecia.

For more information, please visit www.topadur.com and follow Topadur on LinkedIn.

About DEBRA Research

DEBRA Research is a non-profit organization dedicated to advancing treatments and cures for Epidermolysis Bullosa (EB), a rare and life-limiting genetic condition. As the research arm of DEBRA Austria – a patient organization established in 1995 to support individuals living with EB – DEBRA Research collaborates globally with academia, biotech, pharma, patient organizations, and regulatory bodies to drive innovation. DEBRA Research focuses on translational research and clinical development to address the unmet needs of people living with EB. Its goal is to accelerate the discovery and development of treatments improving their quality of life, while striving for a future where EB is curable – a “world without EB.”

For more information, please visit www.debra-research.org and follow us on LinkedIn.

Contacts

DEBRA Research
Prof. Hubert Trübel
info@debra-research.org

Topadur Pharma AG
Yoshita Bhide
Media Communications
+41 44 755 44 66
yoshita.bhide@topadur.com

Media inquiries

MC Services
Anne Hennecke, Dr. Johanna Kobler, Julia Bittner
+49 89 210 2280
contact@mc-services.eu
 

Disclaimer (Topadur Pharma AG)

TOP-N53 and the other compounds referred to in this press release are investigational and have not been approved by any regulatory authority. The program in dystrophic epidermolysis bullosa is at the preclinical stage; the safety and efficacy of these compounds in epidermolysis bullosa have not been established.

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Topadur Pharma AG (Topadur). This publication may contain certain forward-looking statements and assessments or intentions concerning Topadur and its business, including the research program described in this release. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Topadur to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. Topadur disclaims any obligation to update these forward-looking statements, assessments or intentions.

28.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

2423720  28.10.2026 CET/CEST

Straumann Group accelerates organic growth to 9.2% and confirms full-year 2026 outlook

Posted on by
  • Third-quarter revenue amounted to CHF 667.1 million, with organic growth accelerating to 9.2%; revenue for the first nine months reached CHF 2.0 billion, up 8.3% organically
  • iEXCEL continued to gain market share in premium implantology
  • Launch of new Straumann F.A.S.T. digitally powered implant treatment solutions, including SIRIOS APS for full-arch scanning, supporting clinical efficiency and practice profitability
  • Growing adoption of Straumann AXS deepens customer engagement and supports recurring sales of implants and treatment consumables
  • Full-year 2026 outlook confirmed: high single-digit organic revenue growth and core EBIT margin expansion of around 140 to 170 basis points at constant 2025 exchange rates

 

revenue by region

Figures refer to continuing operations, 

in CHF million

 

Q3 2026

Q3 2025

9M 2026

9M 2025

Europe, Middle East & Africa (EMEA)

256.0

234.0

829.5

784.4

 Change CHF

9.4%

8.2%

5.8%

6.6%

 Change (CER[1])

10.5%

11.2%

8.9%

9.7%

 Change organic

10.5%

11.2%

8.9%

9.7%

 % of Group total

38.4

38.9

40.5

40.2

 

 

 

 

 

North America (NAM)

174.9

161.6

527.3

517.4

 Change CHF

8.2%

(0.8%)

1.9%

(0.9%)

 Change (CER1)

7.5%

5.7%

7.9%

3.3%

 Change organic

7.5%

5.7%

7.9%

3.3%

 % of Group total

26.2

26.8

25.8

26.5

 

 

 

 

 

Asia Pacific (APAC)

165.6

144.3

490.4

475.8

 Change CHF

14.8%

(3.4%)

3.1%

9.4%

 Change (CER1)

10.3%

3.2%

6.1%

14.1%

 Change organic

10.3%

3.2%

6.1%

14.1%

 % of Group total

24.8

24.0

24.0

24.4

 

 

 

 

 

Latin America (LATAM)

70.5

62.3

199.4

172.8

 Change CHF

13.1%

9.8%

15.4%

4.2%

 Change (CER1)

6.5%

18.0%

12.1%

17.7%

 Change organic

6.5%

18.0%

12.1%

17.7%

 % of Group total

10.6

10.3

9.7

8.9

 

 

 

 

 

Group

667.1

602.2

2 046.5

1 950.4

 Change CHF

10.8%

2.9%

4.9%

4.9%

 Change (CER1)

9.2%

8.3%

8.3%

9.6%

 Change organic

9.2%

8.3%

8.3%

9.6%

 

Basel, October 28, 2026: Straumann Group reported third-quarter revenue of CHF 667.1 million, representing 9.2% organic growth and a 10.8% increase in Swiss francs compared with the prior-year period. Revenue for the first nine months reached CHF 2.0 billion, up 8.3% organically. Following the strong second-quarter performance, organic growth accelerated further, with all regions contributing. Europe, Middle East and Africa (EMEA) and Asia Pacific (APAC) delivered double-digit growth. North America (NAM) delivered very solid growth in a soft demand market. In Latin America (LATAM), growth was driven primarily by the Hispanic markets outside Brazil, where lower implant penetration provides further opportunities for expansion. Premium implants, the Group’s challenger implantology brands and digital solutions supported the performance. In orthodontics, the transformation is progressing as planned, with new ClearCorrect solutions and digital launches improving treatment efficiency and strengthening the brand’s value proposition.

 

Guillaume Daniellot, Chief Executive Officer, commented: “I am proud of our teams for delivering another strong quarter. Continued share gains for iEXCEL reinforce our leadership in premium implantology, while Neodent keeps on expanding access to treatment in more markets.

Our intraoral scanners have accounted for one of the largest shares of units sold worldwide so far this year. Powered by the new SIRIOS APS unique full-arch scanning technology, the new Straumann F.A.S.T. Full Arch workflow significantly improves the efficiency of advanced full arch treatments. Straumann AXS brings this seamless end to end solution together and further supports practice profitability, avoiding significant investment in additional expensive devices. With those innovations, we remain confident in delivering our full-year outlook.

Finally, after almost 20 years with Straumann Group, I feel honored and humbled to have contributed to its transformation and success, through having always focused on constantly creating value for our customers worldwide. I thank our colleagues, customers and partners for their trust and look forward to the Group’s next chapter under Christopher’s leadership.”

 

REGIONAL PERFORMANCE IN THE THIRD QUARTER

EMEA – Double-digit growth led by premium and challenger implantology

EMEA generated revenue of CHF 256.0 million with +10.5% organic growth. Premium implantology strengthened during the quarter, with iEXCEL continuing to attract new customers and drive conversions. Neodent and Anthogyr supported growth in the Group’s challenger implant segment. The “DACH” region, comprising Germany, Austria and Switzerland, made important contributions, alongside strong momentum in Poland, Romania and Hungary. Educational events, including the International Esthetic Days (iED) and the European Association for Osseointegration (EAO) Congress, strengthened customer engagement and introduced new treatment solutions. ClearCorrect continued to expand in selected European markets, supported by a more focused allocation of resources.

 

NAM – Growth supported by implantology and digital solutions

North America generated revenue of CHF 174.9 million with +7.5% organic growth, delivering very solid growth despite cautious consumer sentiment and broadly stable patient flow. Premium implantology and Neodent progressed well supported by a dynamic pace of customer conversions.

Continued demand for intraoral scanners also contributed to the good performance. ClearCorrect grew in the competitive clear-aligner market, supported by digital tools to assess cases and monitor treatment remotely.

 

APAC – Double-digit growth and strong performance outside China

Asia Pacific generated revenue of CHF 165.6 million, with organic growth accelerating to 10.3%. APAC excluding China performed well in the third quarter with strong growth in Japan and India, supported by iEXCEL and commercial activities around our challenger brands across Southeast Asia. China returned to growth after several challenging quarters marked by uncertainty surrounding volume-based procurement (VBP), contributing to the region’s stronger performance. Rules for the next round of VBP for dental implants have not yet been announced, and implementation is currently anticipated in the first quarter of 2027. The Group’s portfolio of brands across price segments and its local manufacturing capabilities position it well to address the market’s evolving needs.

 

LATAM – Neodent drives further growth by expanding to Hispanic markets

Latin America generated revenue of CHF 70.5 million with +6.5% organic growth, a moderation from the first half of the year. In Brazil, the region’s largest and more mature implant market, patient flow through large dental groups lost momentum and purchasing slowed. Scanner sales also normalized after rapid adoption last year. These developments weighed on regional growth, while Neodent continued to expand in Hispanic markets, particularly Mexico and Colombia, where implant penetration is lower. Premium implantology advanced, and the Group is expanding its coverage of private practices in Brazil to reach more clinicians. In September, the Group opened its third Neodent factory in Curitiba, adding capacity for the brand’s global expansion.

 

STRATEGIC Update

Full arch – Digitally powered treatment from scan to new teeth

Full-arch restorations, which replace all teeth in one jaw with a fixed solution supported by multiple implants, represent a substantial growth opportunity across the Group’s markets. Straumann’s intraoral scanners have been among the global leaders in units sold so far this year, giving the Group a strong base to reach more practices. The new SIRIOS APS (Arch Positioning System) uses unique small reference components on iEXCEL implants to capture their positions digitally, offering a cost-effective alternative to conventional impressions or dedicated and expensive scanning equipment for full-arch treatments. It forms part of Straumann F.A.S.T. (Fast, Accurate, Simple, Trusted), a family of new digitally powered treatment workflows connecting scanning, planning, implant placement and restoration. The new full-arch workflow allows clinicians and dental laboratories to work on the same digital case, aiming to reduce treatment time, improve practice efficiency and get patients to new teeth sooner.

 

Straumann AXS – Growing adoption creates lasting customer value

Strong growth in intraoral scanner sales, particularly SIRIOS, is bringing more clinicians into Straumann’s digital ecosystem. Straumann AXS, the Group’s open cloud-based platform, connects scanning, treatment planning and product ordering and now has more than 20 000 active users. Initial customer analysis is indicating that revenue from an AXS user is growing faster than the non-user group, as reorder rates for AXS customers are substantially higher than for non-AXS customers.

By bringing these steps into clinicians’ daily workflows and making repeat ordering easier, AXS supports lasting customer relationships and recurring sales of implants and treatment consumables.

 

ClearCorrect – A sharper offering for priority markets

ClearCorrect achieved double-digit growth in its priority markets as the orthodontics transformation progressed. Focusing commercial resources on these markets and improving production and operations have reduced costs. In October, ClearCorrect began rolling out a broader wave of innovations for general practitioners, including outcome simulation linked to SIRIOS scanning and additional aligner trimline options in selected markets. Together with Case Assessment, which helps clinicians select suitable cases, and RemoteCare, which supports follow-up between visits, these tools make aligner treatment easier to integrate into general dental practices. The stronger offering and more efficient cost base reinforce ClearCorrect’s position in its target segment and keep the business on track to reach break-even by the end of 2027.

 

Renata Putnik to assume the Chief People Officer role on January 1, 2027

Arnoud Middel has decided to leave Straumann Group at the end of 2026. We thank him for his dedicated leadership and lasting contribution to our global People & Culture organization and talent development, as well as for supporting Renata Putnik’s development which has helped secure a strong internal succession, reflecting the depth of talent at Straumann Group and ensuring continuity in People & Culture leadership as we enter 2027.

Renata Putnik will succeed him as Chief People Officer on January 1, 2027. In more than ten years at Straumann Group, she has held global and regional HR roles and most recently led HR in North America. The Group welcomes her appointment, recognizing her business acumen, strategic perspective and collaborative leadership, alongside her deep understanding of the company and its culture.

 

OUTLOOK FOR THE FULL-YEAR 2026 – BARRING UNFORESEEN EVENTS

Straumann Group continues to expect high single-digit organic revenue growth for the full-year 2026 and confirms its profitability guidance, raised in June, for core EBIT margin expansion of around 140 to 170 basis points at constant 2025 exchange rates. The improvement is expected to be evenly distributed between the first and second half of the year.

The Group remains confident in its ability to deliver on its outlook, supported by the significant growth opportunities in its global CHF 20 billion addressable market, its resilient business model with strong market positions in a continued volatile environment, its innovation and transformation initiatives, and its highly engaged, entrepreneurial culture driving disciplined execution. Its broad global footprint provides a solid foundation for capturing significant growth opportunities in the global oral care market.

 

About Straumann Group

The Straumann Group (SIX: STMN) is a global leader in tooth replacement and orthodontic solutions that restore smiles and confidence. It unites global and international brands that stand for excellence, innovation and quality in replacement, corrective and digital dentistry, including Anthogyr, ClearCorrect, Medentika, Neodent, NUVO, Straumann and other fully/partly owned companies and partners. In collaboration with leading clinics, institutes and universities, the Group researches, develops, manufactures and supplies dental implants, instruments, CADCAM prosthetics, orthodontic aligners, biomaterials and digital solutions for use in tooth correction, replacement and restoration or to prevent tooth loss.

 

Headquartered in Basel, Switzerland, the Group currently employs around 12 000 people worldwide. Its products, solutions and services are available in more than 100 countries through a broad network of distribution subsidiaries and partners.

***

Straumann Holding AG, Peter Merian-Weg 12, 4002 Basel, Switzerland

Phone: + 41 (0)61 965 11 11

Homepage: www.straumann-group.com

 

Contacts

Corporate Communications

Investor Relations

Silvia Dobry:

+41 (0)61 965 15 62

Marcel Kellerhals:

+41 (0)61 965 17 51

Marc Kaiser:

+41 (0)61 965 16 80

Derya Güzel:

+41 (0)61 965 18 76

E-mail: corporate.communication@straumann.com

E-mail: investor.relations@straumann.com

 

analysts’ and media conference call

Straumann Group will present its 2026 third-quarter results to representatives of the financial community and media in a webcast conference call today at 10.30 a.m. CET. The webcast can be accessed via www.straumann-group.com/webcast. A replay of the webcast will be available after the conference.

 

If you intend to ask a question during the Q&A session, we kindly ask you to pre-register for the conference call through this link. We also recommend that you download the presentation file in advance using the conference call.

 

Presentation

The conference presentation slides are attached to this release and available on the Media and Investors pages at www.straumann-group.com.

 

 

upcoming corporate / Investor events

2026

Event

Location

October 29, 2026

Roadshow Bank of America

Paris

November 4, 2026

Roadshow J.P. Morgan

London

November 5, 2026

ZKB Swiss Equity Conference

Zurich

November 10-11, 2026

UBS European Conference

London

November 24, 2026

Kepler Cheuvreux Geneva Day

Geneva

December 7-8, 2026

Roadshow Kepler Cheuvreux

Brussels, Amsterdam

December 8-9, 2026

Roadshow Barclays

New York, Boston

December 14-15, 2026

Roadshow ODDO BHF

Paris

Dec 31, 2026 – Feb 23, 2027

Quiet period

 

February 24, 2027

Full-year 2026 results

Basel

 

Disclaimer

This press release contains forward-looking statements that reflect the current views, beliefs and expectations of management at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, pandemics, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside Straumann’s control. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Straumann is providing the information in this release as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events, or otherwise. This release constitutes neither an offer to sell nor a solicitation to buy any securities.

 

###

[1] Constant exchange rate (CER) equals prior-year figures at 2025 currency exchange rates

BIO-Europe 2026 to Convene Global Biopharma Leaders in Cologne as Dealmaking Confidence Grows

Posted on by

Informa Connect

/ Key word(s): Conference

BIO-Europe 2026 to Convene Global Biopharma Leaders in Cologne as Dealmaking Confidence Grows

27.10.2026 / 15:00 CET/CEST

The issuer is solely responsible for the content of this announcement.

BIO-Europe 2026 to Convene Global Biopharma Leaders in Cologne as Dealmaking Confidence Grows

London, UK – October 27, 2026 – BIO-Europe 2026 will bring together more than 6,000 senior executives from the global biotech, pharmaceutical, and investment sectors in Cologne, Germany, November 9–11, 2026. Now in its 32nd edition, the event comes at a time of renewed confidence in biopharma dealmaking, despite continued financing challenges.

“While 75% of senior biopharma leaders expect appetite for partnering and M&A to increase over the next 12 months. The industry continues to face fundamental questions about how scientific innovation is financed, developed, and brought to patients,” said Claire Macht, Senior Portfolio Director, Europe, Informa Connect. “BIO-Europe provides a neutral platform for senior leaders to challenge established approaches, exchange perspectives, and address the strategic decisions shaping the future of biopharma.”

The findings, from the inaugural Biopharma C-Suite Agenda Survey 2026 (81 senior executives, including 50 CEOs), will anchor BIO-Europe’s Big Picture Plenary Series.

Rethinking Europe’s Biotech Business Models and Financing

As European biotech companies navigate changing capital markets and regulatory environments, industry leaders are increasingly questioning whether established business models can support the next generation of breakthrough therapies.

“CEOs need to speak up: when governments make drug development harder, patients pay the price. Titans must take responsibility,” said Jeremy Levin, Prior CEO Teva Pharmaceuticals. “Big venture funds must back young, science-based companies, or Europe will keep exporting the science and buying back the medicines. Now is the time to invest in innovation.”

“There is now a critical pre-clinical funding gap in Europe as bigger VC funds focus on later-stage clinical development,” said Edwin Moses, Chairman of NanoSyrinx, LabGenius, and Avantium. “These big funds should consider creating new agile vehicles with specialist managers and risk appetite to ensure there is a biotech product pipeline for the future. Innovation in speeding up regulatory pathways is a major opportunity for Europe to lead the way – let’s take the lead and simplify.”

Levin and Moses will debate these issues further at the Big Picture plenary, “Building a Biotech in a Changing World – Europe’s Choices,” examining whether traditional biotech business models can sustain breakthrough innovation amid shifting capital markets, platform-based company creation, and advances in AI.

These challenges will be explored further in a second Big Picture plenary, “Building a Competitive and Impactful European Biotech Community: Perspectives from the European Life Sciences Coalition and CEOs.” The session will introduce the newly established European Life Sciences Coalition (ELSC) and invite participants to support an open letter to European leaders. Moderated by Melanie Senior, the discussion will feature representatives from Andera Partners, Angelini Ventures, Tubulis, and argenx, examining how institutional capital, regulatory pathways, and deeper public capital markets can support biotech company creation and growth in Europe.

Building Globally Competitive Biotech Ecosystems

Beyond financing and regulatory reform, the conference will examine how innovation ecosystems can help biotech companies grow and compete internationally. The session “Building the Next Global Biotech Hubs: What Makes an Innovation Ecosystem Work?” will explore how talent, research infrastructure, investment, and industry collaboration combine to build successful life sciences clusters.

As host region, North Rhine-Westphalia provides an example of an established life sciences ecosystem, bringing together industry, research institutions, and healthcare organizations.

“North Rhine-Westphalia combines scientific excellence with a strong and diverse life sciences industry. Hosting BIO-Europe in Cologne puts our regional capabilities on an international stage,” said Dr. Stefan Rensch of Bio.NRW. “For our companies and research institutions, the event offers direct access to potential investors, pharmaceutical partners, and international markets, helping turn the region’s research and innovation strengths into commercial opportunities.”

Partnering and Registration for BIO-Europe 2026

One-to-one partnering is now open through partneringONE®.

A Digital Partnering Pass offers virtual partnering days on November 17–18, 2026, plus on-demand content, including company presentations and panel discussions.

Registration is open via the the BIO-Europe website, with discounted rates available through November 6, 2026.

About Informa Connect

Informa Connect, a division of Informa PLC, creates global platforms where industries connect, learn, and collaborate through events, digital services, and professional communities. Through its life sciences portfolio, Informa Connect brings together senior executives, investors, and strategic partners to exchange insights, build relationships, and drive innovation across global markets.

For more information, please visit: https://informaconnect.com/bioeurope/

Follow BIO-Europe 2026 on LinkedIn or X @EBDGroup (hashtag: #BIOEurope2026)

Media Contacts:
Informa Connect contacts

Ryan Hui
lifesciencepress@informa.com

MC Services AG contacts

Brittney Sojeva
Senior Consultant
brittney.sojeva@mc-services.eu
+49 211 529 252 14

27.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

2423008  27.10.2026 CET/CEST

PolyPeptide announces results of the extraordinary general meeting of shareholders

Posted on by

PolyPeptide Group

/ Key word(s): AGMEGM

PolyPeptide announces results of the extraordinary general meeting of shareholders

26.10.2026 / 19:10 CET/CEST

Media Release

PolyPeptide announces results of the extraordinary general meeting of shareholders

Baar, 26 October 2026 – PolyPeptide Group AG (“PolyPeptide”) (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, announced that the shareholders approved all proposals by its board of directors (the “Board”) at today’s extraordinary general meeting of shareholders.

In particular, the shareholders elected John Chongbo Rim, Seungho Ryu, Cheol Woo Ryu, Mihyun Yang and Joonkyung Seong as members of the Board for a term of office ending at the conclusion of the next annual general meeting. John Chongbo Rim was elected as chair of the Board, and Cheol Woo Ryu and Seungho Ryu were elected as members of the Remuneration and Nomination Committee, in each case for a term of office ending at the conclusion of the next annual general meeting. All elections are subject to and effective as of the settlement of the public tender offer by Samsung Peptide AG, a wholly owned subsidiary of Samsung Biologics Co., Ltd., for all publicly held registered shares of PolyPeptide.

The shareholders also resolved, subject to the satisfaction or waiver of all of the offer conditions set forth in the offer prospectus of Samsung Peptide AG dated 31 August 2026 (the “Offer Prospectus”), other than the offer condition set forth in section B.7.1(e) of the Offer Prospectus, to remove from the articles of association of PolyPeptide the transfer restrictions (Vinkulierung) and the voting limitations (Stimmrechtsbeschränkungen).

 

Contact

PolyPeptide Group AG   
Strategic Marketing and Corporate Communications
Laura Rosso    
mediateam@polypeptide.com
T: +41 43 502 0580

PolyPeptide Group AG 
Finance / Investor Relations
Tim Brandl
investorrelations@polypeptide.com 
T: +41 43 502 0580 
 

About PolyPeptide

PolyPeptide Group AG and its consolidated subsidiaries (“PolyPeptide”) is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide serves a fast-growing market, offering products and services from pre-pre-clinical to commercial stages. Its broad portfolio reflects the opportunities in drug therapies across areas and with significant exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. For more information, please visit polypeptide.com.

@PolyPeptide — follow us on LinkedIn

Forward-looking Information and Statements

This media release has been prepared by PolyPeptide Group AG and contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual developments to differ materially from those expressed or implied in this release. PolyPeptide Group AG is providing the information in this release as of this date and, except as required by applicable laws or regulations, does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.

 

Additional features:

File: PolyPeptide_EGM Results 2026_ENG

End of Media Release
Language: English
Company: PolyPeptide Group
Neuhofstrasse 24
6340 Baar
Switzerland
Phone: +41435020580
E-mail: mediateam@polypeptide.com
Internet: www.polypeptide.com
ISIN: CH1110760852
Valor: 111076085
Listed: SIX Swiss Exchange
EQS News ID: 2422544

 
End of News EQS News Service

2422544  26.10.2026 CET/CEST

Viromed Medical AG: Successful Completion of Capital Increase

Posted on by

Viromed Medical AG

/ Key word(s): Capital Increase

Viromed Medical AG: Successful Completion of Capital Increase

26.10.2026 / 17:52 CET/CEST

The issuer is solely responsible for the content of this announcement.

Viromed Medical AG: Successful Completion of Capital Increase

Rellingen, October 26, 2026 – Viromed Medical AG (“Viromed”; ISIN: DE000A40ZVN7) has successfully completed the capital increase announced today. A total of 450,000 new registered no-par value shares were placed at a placement price of EUR 4.50 per share. The gross proceeds amount to approximately EUR 2 million and will be used to finance the company’s working capital.

Subject to the registration of the implementation of the capital increase in the commercial register, the share capital will increase from EUR 21,250,000 by EUR 450,000 to EUR 21,700,000. The capital increase was carried out by partially utilizing the Authorized Capital 2025 and with the exclusion of the shareholders’ subscription rights.

 

About Viromed Medical AG

Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region and beyond. Viromed is pursuing the goal of further advancing the use of cold plasma technology in medicine in the coming years and realizing the corresponding growth potential.

www.viromed-medical-ag.de

Contact Viromed

E-Mail: kontakt@viromed-medical.de
 

Press contact

E-mail: viromed@kirchhoff.de

26.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Language: English
Company: Viromed Medical AG
Hauptstraße 105
25462 Rellingen
Germany
E-mail: kontakt@viromed-medical.de
Internet: https://www.viromed-medical-ag.de/
ISIN: DE000A40ZVN7
WKN: A40ZVN
Listed: Regulated Unofficial Market in Dusseldorf, Frankfurt, Hamburg, Tradegate BSX
LEI Code: 894500XR05MYCVCCR171
EQS News ID: 2422458

 
End of News EQS News Service

2422458  26.10.2026 CET/CEST

Bronwyn Brophy O’Connor to become CEO of Carl Zeiss Meditec Group in December 2026

Posted on by

Carl Zeiss Meditec AG

/ Key word(s): Personnel

Bronwyn Brophy O’Connor to become CEO of Carl Zeiss Meditec Group in December 2026

26.10.2026 / 10:30 CET/CEST

The issuer is solely responsible for the content of this announcement.

Jena / Oberkochen, October 26, 2026
 
Bronwyn Brophy O’Connor to become CEO of Carl Zeiss Meditec Group in December 2026
International medtech executive brings extensive experience in customer-focused innovation and business transformation

Bronwyn Brophy O’Connor, currently CEO of the Vitrolife Group in Sweden, will take over as CEO of Carl Zeiss Meditec AG on December 1, 2026. On the same date, she will join the Executive Board of Carl Zeiss AG with responsibility for the Medical Technology segment. Her appointment as successor to current CEO Andreas Pecher had been first announced in May 2026.

With the start date now confirmed, she will assume leadership of Carl Zeiss Meditec Group from Andreas Pecher, who has served as interim CEO since January 1, 2026.

“I am delighted to join Carl Zeiss Meditec and the ZEISS Group. The company combines deep scientific expertise, close customer relationships and a strong commitment to improving patient care. I look forward to working with our teams and customers to build on these strengths, advance innovation and successfully shape the next stage of the company’s transformation,” said Bronwyn Brophy O’Connor.

“With Bronwyn Brophy O’Connor, Carl Zeiss Meditec is gaining an internationally experienced medtech executive who will bring a strong customer and innovation perspective to the company. We wish her a great start,“ said Peter Kameritsch, Chairman of the Supervisory Board of Carl Zeiss Meditec AG.

“We would like to thank Andreas Pecher, both for his temporary dual role as CEO of the ZEISS Group and interim CEO of Carl Zeiss Meditec AG, and for providing important momentum during this period. With her excellent skills, Bronwyn Brophy O’Connor will now be able to further advance the strategy and transformation of the Medical Technology segment forward and contribute to the success of the ZEISS Group,” said Dr. Michael Bolle, Chairman of the Supervisory Board of Carl Zeiss AG.

Effective December 1, 2026, the Management Board of Carl Zeiss Meditec AG will comprise Bronwyn Brophy O’Connor as CEO and Justus Wehmer as CFO.

The Executive Board of Carl Zeiss AG will comprise Andreas Pecher (President and CEO), Stefan Müller (CFO), Bronwyn Brophy O’Connor (Head of the ZEISS Medical Technology segment), Sven Hermann (Head of the ZEISS Consumer Markets segment), Dr. Frank Rohmund (Head of the ZEISS Semiconductor Manufacturing Technology segment), and Dr. Marc Wawerla (Head of the ZEISS Industrial Quality & Research segment).

 

Short profiles:

Bronwyn Brophy O’Connor studied at Dublin City University in Ireland. After earning a bachelor’s degree in International Marketing and Languages (Spanish and French), she completed her Master of Business Administration in 2002. She started her career at Johnson & Johnson in 1997, serving in roles of increasing seniority and ending her career there as General Manager of the Cardiovascular Care Group for the U.K. & Ireland in 2012. Bronwyn then joined Covidien, which was later acquired by Medtronic to form the largest medtech company globally. From 2013 until 2018, she first served as Vice President Early Technologies EMEA and later as President Women’s Health at Medtronic in Boston, USA. In 2019, Bronwyn joined Thermo Fisher Scientific as President for the EMEA region and one year later was promoted to Global President of the Immunodiagnostics Division in Uppsala, Sweden. She has worked internationally, including in Ireland, Spain, the U.K., Switzerland, Sweden and the U.S. Since 2023, Bronwyn Brophy O’Connor has been CEO of the Vitrolife Group, a global medtech company publicly listed on the NASDAQ Stockholm and headquartered in Gothenburg, Sweden.

Andreas Pecher studied physics at the University of Würzburg, Germany, and the University of Texas at Austin, USA. He earned a Master of Business Administration (MBA) at the Kellogg School of Management as well as a Master of Engineering Management at the McCormick School of Engineering. He began his career at Motorola (today NXP) in Texas, USA, in 1998. After completing his MBA in 2005, Andreas Pecher worked as a project manager at McKinsey & Company in Germany. Starting in 2010, he headed the Strategy and Business Development department at the solar company Renewable Energy Corporation in Oslo, Norway, and Munich, Germany. In 2013, Andreas Pecher joined the ZEISS Semiconductor Manufacturing Technology (SMT) segment as Head of Strategic Business Development in Oberkochen, Germany. In 2015, he became Head of the Semiconductor Mask Solutions strategic business unit (SMS SBU) and, starting in 2017, headed the Semiconductor Manufacturing Optics strategic business unit. In 2022, Andreas Pecher became Head of the ZEISS SMT segment and was simultaneously appointed a Member of the Executive Board of Carl Zeiss AG. He was named President and CEO of Carl Zeiss AG effective April 1, 2025. In this role, he also took on the interim position as CEO of the publicly listed Carl Zeiss Meditec AG on January 1, 2026, becoming Head of the Medical Technology segment.
 

Contact for investors and the press
Sebastian Frericks
Head of Group Finance & Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
Email: investors.med@zeiss.com
www.zeiss.com/newsroom
 
About Carl Zeiss Meditec AG
Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the TecDAX and SDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,784 employees worldwide, the Group generated revenue of €2,228m in fiscal year 2024/25 (to 30 September).
The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company’s presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG’s shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.
For more information visit our website at www.zeiss.com/med

 

26.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Language: English
Company: Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena, Germany
Germany
Phone: +49 (0)3641 220-0
Fax: +49 (0)3641 220-112
E-mail: investors.med@zeiss.com
Internet: www.zeiss.de/meditec-ag/ir
ISIN: DE0005313704
WKN: 531370
Indices: SDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX
LEI Code: 529900GRL4MZ8NMOOK95
EQS News ID: 2422052

 
End of News EQS News Service

2422052  26.10.2026 CET/CEST

Viromed Medical AG resolves to conduct a capital increase through a cash contribution, excluding shareholders’ subscription rights

Posted on by

Viromed Medical AG / Key word(s): Capital measures / Capital increase

Viromed Medical AG resolves to conduct a capital increase through a cash contribution, excluding shareholders’ subscription rights

26-Oct-2026 / 08:59 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group.

The issuer is solely responsible for the content of this announcement.

Viromed Medical AG resolves to conduct a capital increase through a cash contribution, excluding shareholders’ subscription rights

Rellingen, October 26, 2026 – With the approval of the Supervisory Board, the Executive Board of Viromed Medical AG (“Viromed”; ISIN: DE000A40ZVN7), resolved today to increase the company’s share capital – excluding shareholders’ subscription rights – from the current EUR 21,250,000 to EUR 21,700,000, an increase of EUR 450,000. This will be achieved by partially utilising Authorised Capital 2025 through the issuance of 450,000 new registered shares with no par value at a placement price of EUR 4.50 each. Initially, the new shares will be subscribed by Small & Mid Cap Investmentbank AG, Munich, and will subsequently be offered to selected investors as part of a private placement.

The gross proceeds from the offering, totalling EUR 2 million, are to be used to finance the company’s working capital.

Notifying person:

Uwe Perbandt, CEO Viromed Medical AG

 

Contact Viromed

E-Mail: kontakt@viromed-medical.de

End of Inside Information

26-Oct-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Language: English
Company: Viromed Medical AG
Hauptstraße 105
25462 Rellingen
Germany
E-mail: kontakt@viromed-medical.de
Internet: https://www.viromed-medical-ag.de/
ISIN: DE000A40ZVN7
WKN: A40ZVN
Listed: Regulated Unofficial Market in Dusseldorf, Frankfurt, Hamburg, Tradegate BSX
LEI Code: 894500XR05MYCVCCR171
EQS News ID: 2421728

 
End of Announcement EQS News Service

2421728  26-Oct-2026 CET/CEST

Galenica continues growth trajectory and confirms outlook for 2026

Posted on by

Galenica continued its growth trajectory in the first nine months of 2026 and increased sales by 5.7% to CHF 3,172.0 million. The main drivers were the continued positive performance in the pharmacy business, strong growth in the home care sector and the integration of the Diagnostics business segment. Temporary restrictions on the product range during the ERP migration resulted in weaker growth in the wholesale business in the third quarter.

Julian Fiessinger, CFO of Galenica, sums up the sales result: “We continued our growth trajectory in the high-margin Products & Care segment in the third quarter. The good performance of our pharmacy business and the strong growth in the home care sector are particularly pleasing. Following the successful ERP switchover, we also expect to see higher growth momentum again in wholesale in the fourth quarter. We are therefore still on track to achieve our guidance.”
 

Pharmacy business continues to develop positively

The Pharmacies Omni-channel business segment continued its positive development, increasing net sales by 6.2% to CHF 1,134.5 million, with organic growth of 4.5%. Sustained strong demand for prescription-only medication once again proved to be a growth driver. These include, in particular, GLP-1-based weight loss products and medications for the treatment of rheumatic diseases. Taking into account the product mix (Rx and OTC products: +5.3%2, non-drugs segment in the consumer healthcare market: +1.1%3), this results in further market share gains for Galenica pharmacies.

Demand for fee-based advisory and healthcare services also continued to increase: Around 290,000 such services were provided in the first nine months (+26%), including 34,000 vaccinations.
 

Consumer healthcare market remains competitive

The Products & Brands business segment generated net sales of CHF 136.5 million (-7.2%), driven in particular by seasonal factors as well as adverse one-off effects in the international business. Due to the portfolio’s focus on flu and cold products, market sales of Verfora products declined by 2.4% in a challenging market environment. By comparison, the Swiss market for over-the-counter healthcare products remained flat, growing by 0.3%3 in the first nine months of 2026.
 

Strong growth in Home Care, continued positive performance in the Diagnostics segment

The Services & Production business segment performed positively in the first nine months of 2026, increasing net sales by 5.8% to CHF 93.6 million; excluding the impact of the closure of Bichsel’s pharmaceutical production operations, growth amounted to 10.5%. The home care business of Bichsel, Lifestage Solutions and Medifilm was once again a key driver of growth. The Diagnostics business segment also continued to develop positively, contributing CHF 91.6 million to the Galenica Group’s net sales in the first nine months of 2026.
 

Successful ERP migration at Galexis

Galexis reached an important milestone in its wholesale business with the successful ERP migration at the Niederbipp site. The final implementation step was completed in September and the foundations were laid for the further development of logistics services and for further increasing automation and efficiency in the wholesale business. The temporary product range restrictions associated with the switchover led to a slowdown in growth in the third quarter. Galenica expects higher growth momentum again in the fourth quarter.

The wholesale business segment generated net sales of CHF 2,441.3 million (+2.8%). In the same period, the overall pharmaceutical market grew by 3.5%2, while the physicians segment generated growth of 2.7%2, and the bricks-and-mortar pharmacy segment grew by 5.3%2. The Logistics & IT Services business segment generated net sales of CHF 58.6 million, representing a slight increase of 0.5% year on year.
 

2026 outlook confirmed

Galenica confirms its outlook for the 2026 financial year, with sales growth of between 5% and 7%, adjusted EBIT1 growth of between 6% and 8% and a dividend at least equal to the previous year’s level.

 

Net sales of the Galenica Group January – September 2026
 

(in million CHF)

Sept. 2026

Sept. 2025

Change

Products & Care segment

1,446.3

1,304.4

10.9%

Pharmacies Omni-Channel

1,134.5

1,068.0

6.2%

Products & Brands

136.5

147.1

-7.2%

Services & Production

93.6

88.4

5.8%

Diagnostics

91.6

7.9

 

Logistics & IT segment

2,498.0

2,432.2

2.7%

Wholesale

2,441.3

2,375.9

2.8%

Logistics & IT Services

58.6

58.4

0.5%

Corporate and eliminations

-772.4

-736.9

 

Galenica Group

3,172.0

2,999.7

5.7%

 

__________

1 See definition in the chapter “Alternative performance measures” in the Annual Report 2025.

2 IQVIA, Pharmaceutical Market Switzerland, YTD September 2026.

3 IQVIA, Consumer Health Market Switzerland, YTD September 2026.

 

 

Additional information on sales figures, explanations of the approach to sales presentation and further information can be found in our sales presentation.

Newron Completes Enrollment of Pivotal Phase 3 ENIGMA-TRS 1 Study

Posted on by

Newron Pharmaceuticals S.p.A.

/ Key word(s): Study

Newron Completes Enrollment of Pivotal Phase 3 ENIGMA-TRS 1 Study

22.10.2026 / 07:00 CET/CEST

The issuer is solely responsible for the content of this announcement.

Newron Completes Enrollment of Pivotal Phase 3 ENIGMA-TRS 1 Study

Total of 618 patients randomized

Topline 12-week data expected in Q1 2027 

Milan, Italy, and Morristown, NJ, USA – October 22, 2026, 07:00 am CEST – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that it has completed enrollment in the pivotal Phase 3 ENIGMA-TRS 1 study evaluating evenamide, its proprietary investigational first-in-class glutamate modulator, as a potential first add-on therapy to second-generation antipsychotics in patients meeting established international consensus criteria for treatment-resistant schizophrenia (TRS). A total of 618 patients have been enrolled at more than 80 study centers in 19 countries across Europe, Asia, Latin America and Canada.

Newron expects to disclose topline 12-week data in Q1 2027. The study will continue under double-blind, placebo-controlled conditions through 52 weeks.

“Reaching this important milestone in the ENIGMA-TRS 1 study reflects the tremendous commitment of investigators and clinical teams, alongside the close collaboration of our academic and regulatory partners, as well as the patients and their families. The study is particularly important given the complexity of conducting a first long-term, randomized, double-blind, placebo-controlled add-on study in patients with TRS, an area of considerable unmet medical need.”

“Of the 996 patients who entered screening, 618 were found to be eligible for the study and were randomized to receive evenamide at 15 mg or 30 mg twice daily, or placebo, following strict adherence to the eligibility criteria by the Independent Eligibility Assessment Committee and five CRO psychiatrists. We look forward to continuing working closely with the investigators and their teams towards successful completion of the study”, said Ravi Anand, MD, Chief Medical Officer of Newron.

Evenamide targets the modulation of excessive release of glutamate in patients suffering from treatment-resistant schizophrenia (TRS).
 

About ENIGMA-TRS

ENIGMA-TRS 1 is an ongoing, international, 52-week, randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy, tolerability, and safety of the 15mg BID and 30mg BID therapeutic doses of evenamide compared to placebo. Patients on second-generation antipsychotics, including clozapine, were required to meet Treatment Response and Resistance Psychosis international consensus criteria for TRS. The study has completed enrollment, with a total of 618 patients enrolled at study centers in 19 countries in Europe, Asia, Latin America, and Canada.

The primary assessment of efficacy and safety of ENIGMA-TRS 1 will be performed 12 weeks after randomization to treatment. Following this initial period, the study will continue to be double-blind and placebo-controlled until the 26- and 52-week time points. The primary efficacy endpoint of the trial will be the change from baseline in the Positive and Negative Syndrome Scale (PANSS) scores at 12 weeks. Newron expects to announce results from the 12-week primary endpoint assessment in Q1 2027.

ENIGMA-TRS 2 is enrolling patients at study centers in Asia and Latin America, with additional sites planned in Europe. The study uses the same screening procedure as ENIGMA-TRS 1. ENIGMA-TRS 2 will include at least 400 patients in a 12-week, randomized, double-blind, placebo-controlled Phase 3 study, designed to evaluate the efficacy, tolerability, and safety of the 15mg BID dose of evenamide compared to placebo. The efficacy and safety analysis will be performed at the 12-week point following successful completion of the study. The FDA clinical hold remains in place at U.S. study centers, where no patients have received evenamide.

About Newron Pharmaceuticals

Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of innovative therapies for patients with diseases of the central and peripheral nervous system. Headquartered in Bresso near Milan, Italy, the Company has a strong track record of advancing neuroscience-based treatments from discovery to market. Newron’s lead compound, evenamide, is a first-in-class glutamate modulator and has the potential to be the first add-on therapy for treatment-resistant schizophrenia (TRS) and for poorly responding patients with schizophrenia. Evenamide is currently being developed in the global pivotal ENIGMA-TRS Phase 3 program. Clinical trial results to date demonstrate the benefits of this drug candidate in TRS as well as in poorly responding patient populations, with significant improvements across key efficacy measures increasing over time, as well as a favorable safety profile, which is uncommon for available antipsychotic medications. Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea. Newron’s first marketed product, Xadago®/safinamide, has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan and South Korea. The product is commercialized by Newron’s partner Zambon, with Supernus Pharmaceuticals holding marketing rights in the U.S., and Meiji Seika responsible for development and commercialization in Japan and other key Asian territories. For more information, please visit: https://www.newron.com and connect with us on LinkedIn.

For more information, please contact:

Newron
Stefan Weber – CEO; pr@newron.com

UK/Europe
Simon Conway / Ciara Martin / Natalie Garland-Collins, FTI Consulting; +44 20 3727 1000, SCnewron@fticonsulting.com  

Switzerland
Valentin Handschin, IRF; +41 43 244 81 54, handschin@irf-reputation.ch

Germany/Europe
Anne Hennecke / Maximilian Schur, MC Services; +49 211 52925227, newron@mc-services.eu

USA
John Fraunces, LifeSci Advisors; +1 917 355 2395, jfraunces@lifesciadvisors.com
 

Important Notices

This document contains forward-looking statements, including (without limitation) about (1) Newron’s ability to develop and expand its business, successfully complete development of its current product candidates, the timing of commencement of various clinical trials and receipt of data and current and future collaborations for the development and commercialization of its product candidates, (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron’s financial resources, and (4) assumptions underlying any such statements. In some cases, these statements and assumptions can be identified by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron’s strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements. By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation difficulties in enrolling clinical trials, negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions. Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron’s research programs, development activities, commercialization plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions. Newron does not undertake any obligation to publicly update or revise forward-looking statements except as may be required by applicable regulations of the SIX Swiss Exchange or the Dusseldorf Stock Exchange where the shares of Newron are listed. This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.

22.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Language: English
Company: Newron Pharmaceuticals S.p.A.
via Antonio Meucci 3
20091 Bresso
Italy
Phone: +39 02 610 3461
Fax: +39 02 610 34654
E-mail: pr@newron.com
Internet: www.newron.com
ISIN: IT0004147952
WKN: A0LF18
Listed: Regulated Unofficial Market in Dusseldorf (Primärmarkt); SIX
LEI Code: 8156002F8C11F80A9740
EQS News ID: 2419974

 
End of News EQS News Service

2419974  22.10.2026 CET/CEST